Monthly Archives: January 2018

Testing for hepatitis B virus (HBV) serologic markers and appropriate vaccination are required in management of IBD patients. We evaluated the immnunogenicity for HBV in IBD patients and response of HBV vaccination those with non-immune state against HBV. Continue reading →

Clinical trial recruitment is often the rate-limiting step in the development of new treatments reaching patients across all disease states. With many competing clinical trials available for inflammatory bowel diseases (IBD) patients, it is important t… Continue reading →

Crohn’s disease (CD) patients all experience psychological distress, but its characteristics are incompletely understood. We report an in-depth cross-sectional study in 297 patients. Continue reading →

A 34-year-old male with Crohn’s disease (CD) (A2-L3-B3) and bad prognostic criteria at diagnosis, was treated with a “top down” strategy with infliximab and azathioprine, with clinical remission but focal endoscopic activity. After 3 years, a tox… Continue reading →

Vitamin D may have a role in immune regulation and be associated with inflammatory bowel disease (IBD) expression. IBD patients are more likely to be vitamin D deficient than the general population. However, it is uncertain if vitamin D monitoring in I… Continue reading →

The role of complementary and alternative medicine (CAM) have been used as adjunctive treatment in inflammatory bowel disease (IBD). It is estimated that 30-50% of IBD patients have used CAMs at some point in their disease course. However, it has been estimated that <50% of CAM users discuss this therapeutic strategy with their gastroenterologists. This study evaluated the frequency at which physicians discuss CAM with their IBD patients. Continue reading →

The treatment of Crohn’s disease has expanded with the development of biologics with different mechanisms of action. Ustekinumab, an inhibitor of IL-23, was approved for use in patients with Crohn’s Disease (CD) in September 2016. We were intereste… Continue reading →

Pten (phosphatase and tensin homolog) regulates microbe-induced immune responses in the gut. Thus, the intestinal deletion of Pten accelerates colitis development in Il10-/- mice. Since some of ambient pollutants inhibit Pten function, and exposure to … Continue reading →

Oral drug delivery is the most attractive pathway for ulcerative colitis (UC) therapy, since it has many advantages. However, this strategy has encountered many challenges, including the instability of drugs in the gastrointestinal tract (GT), low targ… Continue reading →

Combination therapy is an emerging approach for treating ulcerative colitis (UC). During the development of UC, TNF-α acts as the major pro-inflammatory cytokine while interleukin-22 (IL-22) plays an important role in preventing mucosal damage. In the… Continue reading →